
Resmed (RMD) Stock
Global maker of sleep apnea and respiratory devices. Here's the price, business snapshot, and what's worth knowing about Resmed in November 2026.
ResMed Inc. (RMD) is a global medical‑technology company best known for devices that treat sleep apnoea, chronic obstructive pulmonary disease (COPD) and other respiratory conditions. It sells CPAP machines, masks, ventilators and a growing suite of cloud-connected software and services aimed at long‑term patient management. Revenue mixes device sales, consumables and recurring digital subscriptions — a model that can support predictable cash flow as the installed base and mask/consumable replacements continue. Key attractions for investors include an ageing population, steady demand for sleep solutions, and ResMed’s push into remote-monitoring and digital health. Risks include reimbursement changes, competition from other device makers, supply‑chain pressures and regulatory approvals; performance can vary and past results do not guarantee future returns. Market cap is about $39.1bn, making it a large-cap healthcare name. This is general educational information, not personalised advice — consider your personal circumstances and tolerance for volatility before investing.
Why It’s Moving

ResMed Analyst Consensus Weighs Growth Potential Against Margin Pressures
- Connected device expansion and international growth are cited as key drivers supporting long-term prospects.
- Rising costs, intense competition, and margin pressures are identified as primary risks affecting current valuation.
- The company leads a list of high-quality dividend growth stocks with an estimated future return potential of 41.60%.

ResMed Analyst Consensus Weighs Growth Potential Against Margin Pressures
- Connected device expansion and international growth are cited as key drivers supporting long-term prospects.
- Rising costs, intense competition, and margin pressures are identified as primary risks affecting current valuation.
- The company leads a list of high-quality dividend growth stocks with an estimated future return potential of 41.60%.
Six-Month Growth Performance
When is the next earnings date for RESMED INC (RMD)?
ResMed has not yet announced a confirmed date for its next earnings report. Based on the historical reporting pattern, where the company typically releases results approximately three months after the previous quarter's close, the next report is expected in February 2027. This upcoming release will cover the fiscal fourth quarter of 2026. Investors should monitor official announcements for the precise scheduling details as they become available.
Stock Performance Snapshot
Analyst Rating
Analysts suggest keeping ResMed's stock as it has potential to rise slightly in value.
Financial Health
ResMed is performing well with strong profits, cash flow, and solid revenue, indicating good financial stability.
Dividend
ResMed's low dividend yield of 1.03% suggests limited payouts to shareholders. If you invested $1000 you would be paid $10.30 a year in dividends (based on the last 12 months).
Why You’ll Want to Watch This Stock
Recurring revenue model
ResMed’s mix of devices plus consumables and subscriptions can create steadier cash flows, though revenues still face reimbursement and demand risks.
Global patient base
An ageing population and rising diagnosis of sleep disorders support long-term demand, but regional regulation and payor policies can affect growth.
Connected‑care push
Investment in cloud platforms and remote monitoring could boost stickiness and services revenue, yet technology adoption and competition may vary.
Why invest with Nemo?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.